Content about Alzheimer's disease

March 26, 2014

Early-stage Alzheimer’s disease, or AD, increasingly is the target of drug development efforts, but there are very few tools that measure the cognitive function of patients with the condition before the onset of dementia. Experts have concluded that it is best to treat patients prior to changes in cognition, before the symptoms of neurodegeneration appear. As a result, scientists have turned to biomarkers to provide some indication of whether AD is likely to develop.

Early-stage Alzheimer’s disease, or AD, increasingly is the target of drug development efforts, but there are very few tools that measure the cognitive function of patients with the condition before the onset of dementia. Experts have concluded that it is best to treat patients prior to changes in cognition, before the symptoms of neurodegeneration appear. As a result, scientists have turned to biomarkers to provide some indication of whether AD is likely to develop.

January 2, 2014

Among patients with mild to moderate Alzheimer disease, a daily dosage of 2,000 IUs of vitamin E, compared to placebo, was effective in slowing functional decline and in reducing caregiver time in assisting patients, according to a study that appeared in the Jan. 1 issue of JAMA.

CHICAGO — Among patients with mild to moderate Alzheimer disease, a daily dosage of 2,000 IUs of vitamin E, compared to placebo, was effective in slowing functional decline and in reducing caregiver time in assisting patients, according to a study that appeared in the Jan. 1 issue of the Journal of the American Medical Association.

July 29, 2013

Dr. Reddy's Labs has launched a generic drug used to treat Alzheimer's disease, the company said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug used to treat Alzheimer's disease, the company said.

The Indian drug maker announced the launch of donepezil hydrochloride tablets in the 23-mg strength, a generic version of Eisai and Pfizer's Aricept. The drug is being launched in 30- and 90-count bottles.

Aricept in the 23-mg strength had sales of about $92.6 million during the 12-month period that ended in May, according to IMS Health.

 

July 9, 2013

The Food and Drug Administration has approved a generic drug for treating Alzheimer's disease, FDA records showed.

SILVER SPRING, Md. — The Food and Drug Administration has approved a generic drug for treating Alzheimer's disease, FDA records showed.

The agency announced the approval of Alvogen's donepezil hydrochloride, a generic version of Aricept, made by Pfizer and Eisai. The generic drug was approved in the 5 mg and 10 mg strengths.

More than 20 other companies also make generic versions of Aricept. The drug is used to treat mild to moderate Alzheimer's, as well as severe forms of the disease.

 

July 8, 2013

More than half of the estimated 5.4 million Americans with Alzheimer's disease and other forms of dementia are at risk of wandering and becoming lost, according to the National Institute on Aging, a figure that has prompted the federal government to develop a series of training videos for police.

WASHINGTON — More than half of the estimated 5.4 million Americans with Alzheimer's disease and other forms of dementia are at risk of wandering and becoming lost, according to the National Institute on Aging, a figure that has prompted the federal government to develop a series of training videos for police.

April 4, 2013

The annual cost of treating dementia in the United States ranges from $157 billion to $215 billion, according to a new study by the RAND Corp.

NEW YORK — The annual cost of treating dementia in the United States ranges from $157 billion to $215 billion, according to a new study by the RAND Corp.

The research organization said that number meant dementia costs more to treat than cancer or heart disease, with the greatest cost coming from institutional and home-based long-term care, as opposed to medical services.

March 12, 2013

Actavis is challenging Novartis' patent on a patch used to treat Alzheimer's disease, Actavis said.

PARSIPPANY, N.J. — Actavis is challenging Novartis' patent on a patch used to treat Alzheimer's disease, Actavis said.

The generic drug maker said it had filed with the Food and Drug Administration an amendment to its regulatory application for rivastigmine transdermal system to include the 13.3 mg-per-24-hours dosage strength, a generic version of Novartis' Exelon. Novartis filed suit against Actavis on Thursday in the U.S. District Court for the District of Delaware seeking to prevent commercialization of the generic version.

December 3, 2012

Merck has started a clinical trial that it hopes will eventually enroll 1,700 patients to evaluate an experimental drug for Alzheimer's disease, the company said.

WHITEHOUSE STATION, N.J. — Merck has started a clinical trial that it hopes will eventually enroll 1,700 patients to evaluate an experimental drug for Alzheimer's disease, the company said.

Merck announced the start of "EPOCH," a combined phase-2 and phase-3 study of the drug MK-8931, a 78-week trial in which patients will take either the drug in the 12-mg, 40-mg or 60-mg doses or placebo.

July 24, 2012

An experimental drug under development by Pfizer and a unit of Johnson & Johnson does not appear effective in Alzheimer's disease patients who carry a certain genotype, according to results of a late-stage clinical trial announced by Pfizer on Tuesday.

NEW YORK — An experimental drug under development by Pfizer and a unit of Johnson & Johnson does not appear effective in Alzheimer's disease patients who carry a certain genotype, according to results of a late-stage clinical trial announced by Pfizer on Tuesday.

April 6, 2012

Sam's Club is offering free screenings for brain health at all of its stores that operate pharmacies this month, the retailer said Friday.

BENTONVILLE, Ark. — Sam's Club is offering free screenings for brain health at all of its stores that operate pharmacies this month, the retailer said Friday.

The company, which has performed more than 1 million health and wellness screenings at it stores since 2011, said it would offer the screenings on April 14 for members and the public, including a memory test and educational materials on Alzheimer's and dementia provided by the Alzheimer's Foundation of America, as well as body mass index, blood pressure and glucose tests.

January 26, 2012

Pfizer is partnering with a division of Johnson & Johnson and a charity organization to launch an initiative to award funding to projects designed to improve the diagnostic identification and tracking of Alzheimer's disease.

NEW YORK — Pfizer is partnering with a division of Johnson & Johnson and a charity organization to launch an initiative to award funding to projects designed to improve the diagnostic identification and tracking of Alzheimer's disease.

January 17, 2012

A late-stage clinical trial to evaluate a drug in Alzheimer's disease patients came up short, the drug's developers said Tuesday.

NEW YORK — A late-stage clinical trial to evaluate a drug in Alzheimer's disease patients came up short, the drug's developers said Tuesday, prompting them to cease its development.

Pfizer and Medivation announced results of the phase-3 "CONCERT" trial of Dimebon (latrepirdine), a trial that had lasted 12 months and enrolled 1,003 patients worldwide. The drug, which the companies have studied since 2009, was originally developed by Soviet Union scientists in the 1980s as an antihistamine.

December 23, 2011

Drug maker Bristol-Myers Squibb and the Gladstone Institutes will collaborate to find new ways to treat Alzheimer's disease, the two said Thursday.

SAN FRANCISCO — Drug maker Bristol-Myers Squibb and the Gladstone Institutes will collaborate to find new ways to treat Alzheimer's disease, the two said Thursday.

November 15, 2011

Kenneth O’Leary, president and founder of Cara Inc., passed away Oct. 12 at home after a long struggle with Alzheimer’s disease.

WARWICK, R.I. — Kenneth O’Leary, president and founder of Cara Inc., passed away Oct. 12 at home after a long struggle with Alzheimer’s disease.

A 50-year industry veteran, O'Leary, 83, started his career as a detail rep for Schieffelin & Co. in New York. He also spent time with Schering (White Labs), Miles (Dome Labs), CR Bard (Davol) and in 1983 founded Cara Inc.

September 22, 2011

Dr. Reddy's Labs has launched a drug for treating Alzheimer's disease, the company said.

NEW YORK — Dr. Reddy's Labs has launched a drug for treating Alzheimer's disease, the company said.

Dr. Reddy's announced the launch of rivastigmine tartrate capsules in the 1.5-mg, 3-mg, 4.5-mg and 6-mg strengths.

The drug is a generic version of Novartis' Exelon. Exelon and other generic versions of the drug had sales of about $92.6 million during the 12-month period ended in June, according to IMS Health.

June 7, 2011

Another generic drug maker has been given the green light to market its version of an Alzheimer's disease treatment.

PITTSBURGH — Another generic drug maker has been given the green light to market its version of an Alzheimer's disease treatment.

Mylan said that its subsidiary, Matrix Labs, has received final approval from the Food and Drug Administration to manufacture and market donepezil hydrochloride tablets in 5-mg and 10-mg strengths. The drug, a generic version of Pfizer and Eisai's Aricept, is used to treat dementia associated with Alzheimer's disease. Mylan said it will launch the product immediately.

June 2, 2011

The Food and Drug Administration has approved a generic drug for Alzheimer’s disease made by Teva Pharmaceutical Industries.

JERUSALEM — The Food and Drug Administration has approved a generic drug for Alzheimer’s disease made by Teva Pharmaceutical Industries.

The FDA approved Teva’s donepezil hydrochloride tablets in the 5-mg and 10-mg strengths.

The drug is a generic version of Aricept, made by Pfizer and Eisai. Branded and generic versions of the drug had sales of about $2.3 billion during the 12-month period ended in March, according to IMS Health.

June 1, 2011

The Food and Drug Administration has approved a generic treatment for Alzheimer’s disease made by Actavis, the drug maker said Tuesday.

MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic treatment for Alzheimer’s disease made by Actavis, the drug maker said Tuesday.

The FDA approved the company’s donepezil hydrochloride tablets in the 5-mg and 10-mg strengths, a generic version of Eisai and Pfizer’s Aricept. Donepezil hydrochloride tablets in the two strengths had sales of about $2.3 billion during the 12-month period ended in March, according to IMS Health.

June 1, 2011

Sandoz has launched generic versions of treatments for Alzheimer’s disease, the generic pharmaceuticals division of Swiss drug maker Novartis said Wednesday.

PRINCETON, N.J. — Sandoz has launched generic versions of treatments for Alzheimer’s disease, the generic pharmaceuticals division of Swiss drug maker Novartis said Wednesday.

Sandoz announced the launch of donepezil hydrochloride film-coated tablets and donepezil hydrochloride orally disintegrating tablets, which are generic versions of Eisai and Pfizer’s Aricept and Aricept ODT, respectively.

Donepezil hydrochloride film-coated and orally disintegrating tablets had sales of $2.3 billion in the 12-month period ended in March, according to IMS Health.

April 11, 2011

A drug originally developed by scientists in the Soviet Union to treat allergies and currently under investigation by Pfizer and Medivation did not yield significant results in a late-stage clinical trial of patients with Huntington disease, a disorder that leads to cognitive decline, the companies said Monday.

NEW YORK — A drug originally developed by scientists in the Soviet Union to treat allergies and currently under investigation by Pfizer and Medivation did not yield significant results in a late-stage clinical trial of patients with Huntington disease, a disorder that leads to cognitive decline, the companies said Monday.

January 17, 2011

Japanese drug maker Takeda Pharmaceutical has signed an agreement with Durham, N.C.-based Zinfandel Pharmaceuticals to develop a test for assessing Alzheimer’s disease risk in adults, the two companies said.

OSAKA, Japan — Japanese drug maker Takeda Pharmaceutical  has signed an agreement with Durham, N.C.-based Zinfandel Pharmaceuticals to develop a test for assessing Alzheimer’s disease risk in adults, the two companies said.

January 5, 2011

BOLOGNA, Italy — Data from a new study by scientists in Italy could help physicians calculate patients’ risks for Alzheimer’s disease and heart attacks. Researchers at the University of Bologna said they found a common genetic link between heart attacks and Alzheimer’s, according to results of a study published in the Journal of Alzheimer’s Disease.


November 7, 2010

According to a study published in the November edition of Alzheimer’s & Dementia: The Journal...

WASHINGTON According to a study published in the November edition of Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, taking docosahexaenoic acid may improve memory and learning in older adults with mild cognitive impairments. The study found that DHA taken for six months improved memory and learning in healthy, older adults with mild memory complaints.

 

November 7, 2010

Eli Lilly's acquisition of a leader in molecular imaging development could boost its Alzheimer's disease...

INDIANAPOLIS and PHILADELPHIA Eli Lilly's acquisition of a leader in molecular imaging development could boost its Alzheimer's disease drug pipeline.

November 3, 2010

Nearly 100 drugs are in development for treating Alzheimer’s disease, according to a new report...

WASHINGTON Nearly 100 drugs are in development for treating Alzheimer’s disease, according to a new report by the main lobby for the pharmaceutical industry.

 

The Pharmaceutical Research and Manufacturers of America said 98 medicines for dementia, mostly Alzheimer’s, were in clinical trials or under review by the Food and Drug Administration.